Bristol Myers and BioNTech Strike $11B Deal for PD-L1xVEGF-A Bispecific

Highlights

• Bristol Myers Squibb and BioNTech ink an $11 billion deal, including $3.5 billion in upfront and non-contingent payments and up to $7.6 billion in milestone-based payments.
• The partnership centers on BNT327, a PD-L1xVEGF-A bispecific in Phase 3 trials for lung cancer and moving toward breast cancer studies.
• BMS and BioNTech will co-develop and co-commercialize BNT327, sharing costs and profits equally.
• The deal follows BioNTech’s $800M acquisition of Biotheus and intensifies competition with Merck and Pfizer in the bispecific immuno-oncology space.
• Analysts see strategic growth potential but remain cautious about survival outcome risks.

Strategic Alliance in Immuno-Oncology

Bristol Myers Squibb (BMS) has entered into a landmark $11 billion agreement with BioNTech, securing a 50% stake in a leading PD-L1xVEGF-A bispecific candidate, BNT327. As part of the deal, BMS will pay $3.5 billion—comprised of $1.5 billion upfront and $2 billion in non-contingent anniversary payments through 2028—alongside up to $7.6 billion in milestone-based payments.

"This leading position has helped BioNTech land a big deal. BMS is paying $1.5 billion upfront. BioNTech will receive a further $2 billion in non-contingent anniversary payments through 2028. BMS has also committed up to $7.6 billion tied to development, regulatory and commercial milestones."

Collaborative Development of BNT327

Under the terms of the partnership, BioNTech grants BMS co-development and co-commercialization rights for BNT327, a PD-L1xVEGF-A bispecific antibody. The companies will jointly develop the asset as a monotherapy and in combination therapies, equally sharing costs and profits. Additionally, both companies retain the flexibility to independently explore further indications.

"Enlisting the support of BMS could help BioNTech to maximize its early-mover advantage by accelerating the exploration and validation of the potential of BNT327."

BioNTech’s Competitive Edge in the Race

BioNTech is positioned just behind Summit Therapeutics in the competitive race to commercialize PD-1/L1xVEGF-A bispecific therapies in the U.S. The German biotech is conducting Phase 3 trials in both small and non-small cell lung cancer and aims to initiate pivotal studies in triple-negative breast cancer later this year. Summit, meanwhile, has released global Phase 3 data for one indication.

"BioNTech is tucked in behind Summit Therapeutics in the race to bring a PD-1/L1xVEGF-A bispecific to the U.S. market."

Strategic Investments and Market Reactions

The deal marks a rapid return on BioNTech’s recent investments, including acquiring global (ex-China) rights to BNT327 for $55 million in 2023 and its $800 million acquisition of Biotheus, the original developer of BNT327. The Biotheus acquisition helped catalyze a broader wave of M&A activity in the bispecific antibody field.

"The deal represents a quick financial win for BioNTech, which bagged ex-China rights to BNT327 in 2023 for $55 million upfront and bought its partner Biotheus outright for $800 million upfront late last year."

Growing Industry Interest

Interest in PD-1/L1xVEGF-A bispecifics has intensified in recent months. Following BioNTech’s acquisition of Biotheus, Merck & Co. joined the race with a $588 million investment. Pfizer followed suit, investing $1.25 billion upfront to partner with 3SBio for a PD-1xVEGF candidate entering Phase 3 trials in China. BMS, meanwhile, had been closely monitoring developments.

"Merck paid $588 million to join the race the day after BioNTech disclosed the Biotheus takeover. Pfizer upped the ante last month by paying 3SBio $1.25 billion upfront for a PD-1xVEGF bispecific."

BMS’s Calculated Approach

Samit Hirawat, M.D., head of development at BMS, outlined the company’s rationale ahead of the deal, emphasizing the need for strong scientific, business, and capital alignment. He noted the significance of early overall survival (OS) and safety data. BMS aims to complement its established immuno-oncology portfolio, which includes Opdivo and Yervoy, with promising next-generation assets like BNT327.

"We've always said capital allocation, the way we think about BD is very important,” Hirawat said. “We've said that we will be disciplined in terms of thinking about our capital allocation. It needs to make sense, not only from the scientific perspective and business perspective, but it also needs to be part and parcel of our capabilities and capacity."

Market Reactions and Analyst Caution

Following the announcement, BioNTech shares surged 11% to over $106 in premarket trading, while BMS shares rose 1% to $48.76. Analysts at William Blair noted the potential of the partnership to support BMS’s long-term growth strategy through the 2030s, while cautioning that the therapeutic class still faces clinical risks related to demonstrating significant overall survival benefit.

"The firm... said the pact 'aligns with the company’s strategy of bolstering its growth profile into the 2030s,' but warned that it carries 'clinical risk of achieving clinically meaningful overall survival benefit.'"